Eligibility of patients with type 2 diabetes for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry

Diabetes, Obesity and Metabolism

Volumn 21, Issue 8, 2019, Pages 1985-1989

  Wittbrodt, Eric ^a   Chamberlain, David ^a   Arnold, Suzanne V ^b,c   Tang, Fengming ^b   Kosiborod, Mikhail ^b,c  

^a ASTRAZENECA   (United Kingdom)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

cardiovascular disease; observational study; SGLT 2 inhibitor; type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; HEMOGLOBIN A1C; ANTIDIABETIC AGENT;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CROSS-SECTIONAL STUDY; DRUG USE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; REGISTER; RETROSPECTIVE STUDY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COMPLICATION; DIABETIC ANGIOPATHY; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATIENT SELECTION;

AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ELIGIBILITY DETERMINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PATIENT SELECTION; PREVALENCE; REGISTRIES; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85065034335     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13738     Document Type: Article

References (19)

1. Food and Drugs Administration 2008. Guidance for industry, diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. https://www.fda.gov/downloads/Drugs/Guidances/ucm071627.pdf. Accessed March 20, 2019
2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.
3. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657.
4. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-357.
5. Kosiborod M, Birkeland KI, Cavender MA, et al. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: results from the CVD-REAL study. Diabetes Obes Metab. 2018;20:1983-1987.
6. Cannon CP, McGuire D, Pratley R, et al. Design and baseline characteristics of the evaluation of ertuglifozin efficacy and safety cardiovascular outcomes trial (VERTIS-CV). J Am Coll Cardiol. 2018;71:A1825.
7. Arnold SV, Inzucchi SE, McGuire DK, et al. Evaluating the quality of comprehensive cardiometabolic care for patients with type 2 diabetes in the U.S.: the Diabetes Collaborative Registry. Diabetes Care. 2016;39:e99-e101.
8. Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ. 2001;323:75-81.
9. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. J Am Coll Cardiol. 2014;63:2935-2959.
10. Birkeland KI, Bodegard J, Norhammar A, et al. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. Diabetes Obes Metab. 2019;21:968-974.
11. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018;393:31-39.
12. Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136:249-259.
13. Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol. 2018;71:2628-2639.
14. Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N. Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world). Circulation. 2018;137:1450-1459.
15. Patorno E, Goldfine AB, Schneeweiss S, et al. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ. 2018;360:k119.
16. Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. Am J Manag Care. 2018;24:S138-S145.
17. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2017;40:S1-S129.
18. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015;21:438-447.
19. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669-2701.